Media Room

Latest News Releases

Sep 12, 2017

Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab)

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has begun dosing in the PROPEL clinical study which will evaluate the efficacy and safety of NKTR-214, the company's lead immuno-oncology...

Sep 6, 2017

Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek®

Nektar Therapeutics (Nasdaq: NKTR) today presented clinical data from the SUMMIT-07 Phase 3 study of NKTR-181, a first-in-class opioid analgesic to treat chronic pain, at the 2017 PAINWeek®...

Sep 6, 2017

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2017 Morgan Stanley Global Healthcare Conference in New York...

Multimedia Libraries

Broadcast Video

Image Gallery

Media Contacts

Dan Budwick
Pure Communications, Inc.
Media@purecommunications...

Follow @NektarNews

Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide